Nilutamide

Androgen Receptor Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Nilutamide is an ofp drug in the Androgen Receptor Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1996. Its mechanism of action is classified as Androgen Receptor Antagonists. DrugCentral lists 1 molecular target, including AR. Recorded indications include Metastatic Prostate Carcinoma.

• Approval status: ofp (first approved 1996 by the FDA).
• Drug class: Androgen Receptor Inhibitor.
• Mechanism of action: Androgen Receptor Antagonists.
• Molecular targets: AR (1 listed in DrugCentral).
• Indications: Metastatic Prostate Carcinoma.
• ATC code: L02BB02 (Anti-androgens).
• Molecular formula: C12H10F3N3O4; molecular weight 317.22 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Metastatic Prostate Carcinoma

Off-label uses (1)

• Advanced Prostatic Carcinoma

Contraindications (5)

• Decreased respiratory function
• Disorder of lung
• Hepatic failure
• Incomplete Testicular Development
• Interstitial pneumonia

Mechanism & targets

• Mechanism of action (MoA): Androgen Receptor Antagonists
• Established pharmacologic class: Androgen Receptor Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Androgen receptor	AR	antagonist	IC50 8.05

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1996-09-19	FDA	—	CONCORDIA PHARMS INC

ATC classification

ATC code	Therapeutic hierarchy
L02BB02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ENDOCRINE THERAPY › HORMONE ANTAGONISTS AND RELATED AGENTS › Anti-androgens

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Nilutamide is on its molecule page.

• Molecular formula: C₁₂H₁₀F₃N₃O₄
• Molecular weight: 317.22 g/mol
• CAS number: 63612-50-0
• InChIKey: XWXYUMMDTVBTOU-UHFFFAOYSA-N
• PubChem CID: 4493

CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nilutamide used for?

DrugCentral lists the following indications for Nilutamide: Metastatic Prostate Carcinoma.

How does Nilutamide work?

Nilutamide is classified as Androgen Receptor Antagonists; its molecular targets in DrugCentral include AR (antagonist).

When was Nilutamide first approved?

Nilutamide was first approved by the FDA in 1996.

What drug class does Nilutamide belong to?

Nilutamide is in the Androgen Receptor Inhibitor class.

What is the chemical formula of Nilutamide?

Nilutamide has the molecular formula C12H10F3N3O4 and a molecular weight of 317.22 g/mol.

Sources

• DrugCentral drug card 1933 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1274 — compound record and bioactivity
• PubChem CID 4493 — chemical identifiers
• DrugBank DB00665 — drug record
• FDA UNII 51G6I8B902 — substance identity
• DailyMed: FDA labels for Nilutamide — current prescribing information (label search)
• UniProt P10275 (AR) — target protein

How this page is built: methodology · editorial policy & corrections.